ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Prognostic Impact and Metastasis Propensity of Grade Group 5 Prostate Cancer Following Permanent Seed Implantation Brachytherapy-Based Trimodality Therapy: Implications for Intensified Staging and Systemic Therapy Optimization.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the prognostic impact of Grade Group (GG) 5 following permanent seed implantation brachytherapy-based trimodality therapy.
methodsWe retrospectively analyzed 352 men with National Comprehensive Cancer Network high-risk prostate cancer treated with trimodality therapy (low-dose-rate brachytherapy, external beam radiation therapy, and androgen deprivation therapy [ADT]) between 2003 and 2019. Staging included computed tomography, magnetic resonance imaging, and bone scintigraphy. Endpoints were biochemical recurrence (BCR; Phoenix definition), overall survival (OS), and cancer-specific survival (CSS). Survival outcomes were assessed using the Kaplan-Meier and log-rank tests. Multivariable Cox proportional hazards models, adjusting for prostate-specific antigen, clinical stage, duration of ADT, and biologically effective dose (BED), evaluated the association between GG5 and BCR. Clinical recurrence patterns post-BCR were assessed.
resultsMedian follow-up was 8.2 years (interquartile range [IQR] 5.4-10.0); median BED was 214 Gy (IQR 207-222). Among three study groups (GG1-3, GG4, and GG5), GG5 (n = 106) exhibited significantly lower BCR-free survival (p = 0.002) and CSS (p = 0.045), while OS was comparable (p = 0.3). GG5 remained an independent risk factor for BCR after the adjustment (vs. GG1-4, hazard ratio 2.78, 95% confidence interval 1.60-4.82, p < 0.001). GG5 recurrences predominantly involved the pelvic nodes or bone, whereas local and visceral metastases were infrequent.
conclusionsThis study demonstrated that GG5 is an independent predictor of BCR and cancer-specific mortality after trimodality therapy. Despite high BED, the propensity for nodal and bone metastases suggests the need for intensified staging and systemic therapy to optimize outcomes for GG5 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.